The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 1.99 — grey zone — between safe and distressedWatch
- Earnings-manipulation signal · Beneish M -3.11 — no flag raisedOK
- Earnings quality 100/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2025, as Embecta Corp. reports it. History and quarterly detail are in the app.
- Pen Needles$784.1M
- Safety$137.8M
- Syringes$124.6M
- Contract Manufacturing$19.9M
- Other$14.0M
Leadership changes
From Embecta Corp.'s own filings, the day they're filed.
- David A. Albritton · member of the board of directors · departureeff. 2025-11-17
- Anthony Roth · President · appointmenteff. 2024-12-02
- Jake Elguicze · Chief Financial Officer · appointmenteff. 2024-08-12
Latest filings
- 8-K · Company announcement2026-05-15
- 10-Q · Quarterly report2026-05-05
- 8-K · Company announcement2026-05-05
- 8-K · Company announcement2026-03-20
- 8-K · Company announcement2026-02-13
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about Embecta Corp., every answer cited🔒
- The Intelligence Brief — added when Embecta Corp.'s brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.